Divis Lab USFDA
The US health regulator has issued a warning letter to the Drug firm Divis Laboratories at Visakhapatnam. However, the company along with few external consultants and subject matter experts are trying to work to address the concerns of the United States Food and Drug Administration (USFDA) and is striving to fully meet the compliance requirements. The company has reportedly not provided the details of the warning letter.
The company said that the laboratories have responded to the USFDA inspection observations with a very appropriate remediation process to overcome the deficiencies which have been observed.
Earlier, when an import alert has been issued the regulator had exempted several products which are being manufactured at the Unit II in Visakhapatnam, said the Divis Laboratories. The exempted products include Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium and BOC core succinate.
However, the company will respond to this warning letter from the USFDA with a detailed plan within the stipulated time. It is also said that earlier, in a regulatory filing the regulator had issued import alert for products which are being made at Visakhapatnam unit citing violation of products made at Visakhapatnam unit citing violation of manufacturing norms and refusal of inspection.
Over the past few months, pickleball has slowly become one of the most talked-about sports…
Chief Minister N. Chandrababu Naidu has renewed his demand for conferment of Bharat Ratna on…
Food in Vizag is no longer just about taste. Somewhere between aesthetic cafes, rooftop dining,…
District Collector M. Abhishikth Kishore has directed the officials concerned to speed up the Bhogapuram…
To ensure a comfortable journey for the travelling passengers, the East Coast Railway has decided…
Vizag Gen Z is not just living life the way it used to. There is…